Selected article for: "acute respiratory syndrome coronavirus and live affect"
Author: Olaimat, Amin N; Aolymat, Iman; Al-Holy, Murad; Ayyash, Mutamed; Abu Ghoush, Mahmoud; Al-Nabulsi, Anas A; Osaili, Tareq; Apostolopoulos, Vasso; Liu, Shao-Quan; Shah, Nagendra P; Olaimat, Amin N.; Al-Nabulsi, Anas A.; Shah, Nagendra P.
Title: The potential application of probiotics and prebiotics for the prevention and treatment of COVID-19.
  • Cord-id: 8cm8cebs
  • Document date: 2020_1_1
    • ID: 8cm8cebs
    Snippet: COVID-19 is a pandemic disease caused by the novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This new viral infection was first identified in China in December 2019, and it has subsequently spread globally. The lack of a vaccine or curative treatment for COVID-19 necessitates a focus on other strategies to prevent and treat the infection. Probiotics consist of single or mixed cultures of live microorganisms that can beneficially affect the host by maintaining the
    Document: COVID-19 is a pandemic disease caused by the novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This new viral infection was first identified in China in December 2019, and it has subsequently spread globally. The lack of a vaccine or curative treatment for COVID-19 necessitates a focus on other strategies to prevent and treat the infection. Probiotics consist of single or mixed cultures of live microorganisms that can beneficially affect the host by maintaining the intestinal or lung microbiota that play a major role in human health. At present, good scientific evidence exists to support the ability of probiotics to boost human immunity, thereby preventing colonization by pathogens and reducing the incidence and severity of infections. Herein, we present clinical studies of the use of probiotic supplementation to prevent or treat respiratory tract infections. These data lead to promising benefits of probiotics in reducing the risk of COVID-19. Further studies should be conducted to assess the ability of probiotics to combat COVID-19.

    Search related documents:
    Co phrase search for related documents
    • abdominal pain and ace receptor: 1, 2, 3, 4, 5, 6
    • abdominal pain and activity composition: 1
    • abdominal pain and acute cardiac injury: 1, 2
    • abdominal pain and acute cardiac injury respiratory distress syndrome: 1
    • abdominal pain and acute infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71
    • abdominal pain and acute kidney injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26
    • abdominal pain and additional research: 1, 2, 3
    • abdominal pain and long period: 1, 2
    • abdominal pain and low number: 1
    • abdominal pain and low respiratory tract: 1
    • abdominal pain and lps lipopolysaccharide: 1
    • abdominal pain and lung gut microbiota: 1, 2
    • abdominal pain and lung health: 1, 2
    • abdominal pain and lung health gut: 1
    • abdominal pain and lung inflammation: 1
    • abdominal pain and lung inflammatory: 1
    • abdominal pain and lung injury: 1, 2, 3, 4, 5
    • abdominal pain and lung microbiome: 1
    • abdominal pain and lymph node: 1, 2, 3, 4, 5, 6, 7, 8